Navigation Links
Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
Date:12/5/2007

ll be set based on evaluation from the first stage pharmacokinetic study using the new formulation. The second stage will evaluate the safety and tolerability of LX6171 oral suspension in subjects exhibiting AAMI and will measure the cognitive effects of LX6171 in these subjects using the Cognitive Drug Research battery, along with other psychometric instruments. The study is being conducted in Europe, with initial results expected by the end of 2008.

About LX6171

LX6171 is an orally-bioavailable small molecule developed by Lexicon scientists to inhibit a membrane protein expressed exclusively in the central nervous system and found at synaptic vesicles and presynaptic membranes of glutamatergic neurons. The protein targeted by LX6171 was identified through Lexicon's large-scale gene knockout program, the Genome5000(TM). Knockout mice lacking this protein showed improved learning and memory compared with controls. In preclinical studies, administration of LX6171 resulted in improved performance in tests of learning and memory in mice. In Phase 1 clinical trials, LX6171 was generally well tolerated at all dose levels and showed good systemic exposure.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, and rheumatoid arthritis. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bris
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Bronstein, Gewirtz & Grossman, LLC ... the securities of Celladon Corporation ("Celladon" or the "Company") ... Peretz Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Celladon and ... 10(b) and 20(a) of the Securities Exchange Act of ...
(Date:4/27/2015)... 27, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report first ... close on Monday, May 11, 2015, followed ... at 4:30pm Eastern.Conference Call & Webcast: Monday, ... Domestic: , 888-556-4997International: , 719-457-2628Conference ID: , ...
(Date:4/27/2015)... , April 27, 2015  Novira Therapeutics, Inc., a ... curative treatment of chronic hepatitis B virus (HBV) infection, ... its lead HBV core inhibitor candidate, NVR 3-778, at ... the Study of the Liver (EASL) in ... of NVR 3-778 from studies performed in a humanized ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... one of Israel,s leading private biotech, pharmaceutical and medical ... Israel. "We are excited to reach this ...
... Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC ... that final results from the phase II OPAL study ... acute myeloid leukemia (AML) were presented by Jorge Cortes, ... Center during the Acute Myeloid Leukemia - Therapy, excluding ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
(Date:4/27/2015)... As ISO 27001 has quickly become ... of all sizes and in all industries, Pivot Point ... for ISO 27001 certification. The information security audit firm ... for ISO 27001 certification. Pivot Point's commitment to ISO ... number of Lead Implementers and Auditors the company employs ...
(Date:4/27/2015)... Guided by the extensive work of its community ... collaboration with organizations around the world to identify proven ... essential actions for organizations committed to patient experience ... systems committed to providing the best in experience will:, ... with committed time and focused intent to shape and ...
(Date:4/27/2015)... PHILADELPHIA, PA (PRWEB) April 27, 2015 ... it will exhibit its wide range of market leading ... to May 7 in Geneva, Switzerland. Vitafoods Europe 2015 ... over 100 countries showcasing the latest research in such ... personalized nutrition. , FMC Health and Nutrition’s booth ...
(Date:4/27/2015)... On May 15, Mount Soma Ashram ... campaign to raise awareness of the vision of Mount ... Somesvara Temple. Ironically, when many of these people moved ... thought they were leaving the social and technological world ... of meditation, service to a higher cause, deep introspection, ...
(Date:4/27/2015)... York, NY (PRWEB) April 27, 2015 ... are creating a seamless referral process for the Health ... with chronic heart failure or diabetes, for instance, may ... most primary physicians coordinate with many other care providers. ... referring hundreds of thousands of patients each year, the ...
Breaking Medicine News(10 mins):Health News:Six Additional New ISO 27001 Lead Implementers Certified for Pivot Point Security 2Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2Health News:Mount Soma Monks Do Social Media 2Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... American Institute of Ultrasound in Medicine (AIUM) and ... the collaborative development of the Practice Guideline for ... Practice of Urology. This guideline has been developed ... the practice of urology and provides direction in ...
... Molecular Medicine (MDC) Berlin-Buch have found out why the ... the world,s most unusual mammals, feels no pain when ... in narrow dark burrows where ambient carbon dioxide (CO2) ... converted into acid, which continuously activates pain sensors. However, ...
... , TUESDAY, Dec. 20 (HealthDay News) -- Increased public ... reasons why child and teen exposure to unwanted online ... States, a new study indicates. However, reports of ... University of New Hampshire Crimes Against Children Research Center. ...
... "disarray and dysfunction" jeopardize access to medical care ... military families, said the American College of Physicians ... with House and Senate leadership. ACP is ... membership organizationin the United States, representing 132,000 internal ...
... A hike in your blood pressure during middle age significantly ... stroke during your lifetime, according to new Northwestern Medicine research. ... maintaining low blood pressure early in middle age to prevent ... developed high blood pressure in middle age or who started ...
... evaluating early kidney injuries in people, doctors monitor blood ... breakdown, to understand the severity of the injury. Creatinine ... an indication of early damage to vital kidney function. ... Missouri researchers have found that even tiny increases of ...
Cached Medicine News:Health News:MDC researchers: Ion channel makes African naked mole-rat insensitive to acid-induced pain 2Health News:MDC researchers: Ion channel makes African naked mole-rat insensitive to acid-induced pain 3Health News:Youth Exposure to Unwanted Internet Sexual Encounters Drops 2Health News:Congress' 'disarray' makes it 'likely' that 27 percent Medicare cut will go in effect 2Health News:New predictor of heart attack or stroke 2Health News:MU researchers find pet kidney injuries are similar to human kidney injuries 2
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... ratchet design provides fingertip ratchet disengagement allowing ... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ...
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... A broad selection of procedurally specific ... and allow easy access to all ... variety of approaches.,Loop Handled Graspers feature ... holds tissue firmly without tearing or ...
Medicine Products: